solomo.ai

Marksans Pharma Ltd (MARKSANS) — shareholding pattern, promoter holding, financials and share price

About Marksans Pharma Ltd (MARKSANS)

Marksans Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MARKSANS and on the BSE under scrip code 524404. Its ISIN is INE750C01026.

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]

Marksans Pharma Limited is an integrated pharmaceutical company focused on research, manufacturing and global distribution of formulation products, with a dominant OTC/store-brand presence in the US and a strong front-end in the UK and Australia; the company operates four manufacturing units, four R&D centres and holds multiple accreditations including USFDA, MHRA, TGA and Health Canada.

In Q3 FY26 Marksans reported operating revenue of ₹754.4 crore, a 10.6% YoY increase, EBITDA of ₹160.7 crore with a 21.3% margin, and 9M FY26 cash generation of ₹263.2 crore alongside a cash balance of ₹824.2 crore as of December 31, 2025, reflecting improved margins driven by raw material softness, FX tailwinds and operating leverage.

Listed peers in Pharmaceuticals: Concord Biotech Ltd, Corona Remedies Ltd, Shilpa Medicare Ltd, Viyash Scientific Ltd, Procter & Gamble Health Ltd, Akums Drugs & Pharmaceuticals Ltd.

Valuation & Returns

10 Jul 2026

At ₹272.35 a share on 10 Jul 2026, Marksans Pharma Ltd (MARKSANS) was valued at a price-to-earnings ratio of 29.38x against an industry P/E of 36.41x and a price-to-book of 5x on a book value of ₹54.44 per share as of Mar 2025. Solomo computes return on equity of 17.03% and return on capital employed of 20.97% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
29.38x
Industry P/E
36.41x
P/B
5x
EPS (TTM)
₹9.27
Book value / share
₹54.44
ROE
17.03%
ROCE
20.97%
ROA
12.97%
Debt / equity
0.13x
Dividend yield
0.29%
EBITDA margin
23.16%
52-week range
₹156 – ₹281.4

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Marksans Pharma Ltd (MARKSANS) reported revenue of ₹2,951 crore, net profit of ₹420 crore and earnings per share of ₹9.22. That compares with revenue of ₹2,623 crore and net profit of ₹383 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹856 crore and net profit ₹149 crore (consolidated).

Consolidated annual results for Marksans Pharma Ltd (MARKSANS), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)1,4911,8522,1772,6232,951
Net profit (₹ cr)187265315383420
EPS (₹)4.515.886.928.49.22
Compound annual growth for Marksans Pharma Ltd (MARKSANS). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth14.11%22.06%21.28%20.46%
Profit growth11.36%37.79%21.88%21.51%
Stock price CAGR20%26%37%5%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 43.87% of Marksans Pharma Ltd (MARKSANS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 17.47% and domestic institutional investors (DII) hold 6.19%. Market capitalisation was ₹12,342 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.

Largest disclosed public shareholders in Jun 2026: ORBIMED ASIA IV MAURITIUS FVCI LIMITED 8.62%, UTI-HEALTHCARE FUND 2.11%, KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK SPECIAL OPPORTUNITIES FUND 1.14%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202643.87%-17.47%6.19%56.13%
Mar 202643.87%-16.76%6.57%56.13%
Dec 202543.87%-8.12%5.91%56.13%
Sep 202543.87%-16.92%5.28%56.13%
Jun 202543.87%-19.88%5.5%56.13%
Mar 202543.87%-22.2%4.56%56.13%
Dec 202443.87%-21.96%4.3%56.13%
Sep 202443.87%-21.31%4.1%56.13%
Every quarter since Mar 2001 Filing data, not investment advice.